← Back to patent-cliff list
Idrebormilast
Tier C — Watch / tradeIdrebormilast
Pfizer Inc.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDE4
Indications (approved)：Plaque psoriasis, Atopic dermatitis, Vitiligo, Rosacea, 脂溢性皮炎
Regional status
US
Phase II
2020-12-21
EU
Phase II
2020-12-21
China
-
Japan
Phase II
2022-09-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Idrebormilast?
Approved indications include: Plaque psoriasis, Atopic dermatitis, Vitiligo, Rosacea, 脂溢性皮炎.
When does the Idrebormilast patent expire?
No public expiry year is available for Idrebormilast yet; this page updates once verified.
How do I get a quote for Idrebormilast intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06